Objective: The purpose of the present investigation was to analyze the effets of zidovudine on the postimplantation embryo and fetus.
formerly called azidothymidine (AZT), was the first agent commercially available for the treatment of symptomatic HIV infection and was shown to be effective. -3 The current recommendations from the Centers for Disease Control (CDC) are that zidovudine therapy be offered to pregnant patients with HIV and near normal CD4 counts to prevent perinatal transmission ofHIV. 4 AIDS was previously considered a disease primarily of homosexual men, s but recent seroprevalence studies indicate that the male-female ratio may be much closer to 1:1. Certain inner city obstetric populations have been shown to have seroprevalence rates as high as 2%, and nearly 50% of the sexual partners of HIV-infected IV drug abusers demonstrate serologic evidence of infection. 6'7 Recent reports indicate that the prevalence of HIV approaches in 250 in the general population, but the rate among pregnant women is much lower, at 1-2 in 1,000.
Zidovudine acts as an antiviral agent by inhibiting viral reverse transcriptase and by terminating viral DNA chain elongation. 8 Host cellular DNA polymerase is also inhibited, but only at concentrations 100 times greater than those required to inhibit viral reverse transcriptase in mammals. 9 The side effects commonly encountered in therapeutic entirely virus-specific. In one study, 24% of zidovudine recipients developed anemia (hemoglobin <7.5 g/dl), and 16% developed neutropenia (<500 cells/ram3).
10
Animal studies have also shown rapid placental transfer of zidovudine, 12 and zidovudine has been shown to cross the placenta in explanted human placental cotyledon studies. 13, 14 The drug may disrupt early embryonic development because, as mentioned previously, the mechanism of action of zidovudine is the inhibition of DNA replication.
Zidovudine was associated with increased preimplantation mouse embryo loss in several studies, [15] [16] [17] [18] but no congenital abnormalities were detectable. The possible mechanism of embryolethality of zidovudine was thought to be due to retarded cell division. 18 Zidovudine is classified by its manufacturer as a pregnancy Category C drug. [6] [7] [8] [9] [10] [11] of pregnancy. This number of animals was chosen to comply with the published recommendations for the design of subprimate animal studies. 19 The absorption of zidovudine through intragastric intubation was documented in a prior investigation conducted in this laboratory in which the placental transfer was analyzed. 12 The greatest number of anatomic structures form in the rat embryo in the period of gestation from days [6] [7] [8] [9] [10] [11] (taking insemination as day 0). By day 11, the neural structures have formed, somite development has occurred, and major organs (including heart, kidney, gastrointestinal tract, thyroid gland, and thymus) and limb buds have developed. 20, 21 The low-dose group (group I) received the adult human dose (10 mg/kg) throughout the major period of embryogenesis (days 6-11), while the medium-dose groups (groups II and III) received roughly 3 times the adult human dosage (30 mg/ kg). The medium-dose groups were comprised of group II, which received the dose early in embryogenesis (days 6-8) and group III, which received the dose later during the period of embryonic development (days 9-11). Group IV, the high-dose group (150 mg/kg/day), receiving 15 times the usual human therapeutic dose, was treated on days [6] [7] [8] [9] [10] [11] . The purpose of the high-dose group was to magnify any teratogenic effect, and the mediumdose groups were intended to place any effect temporally within the period of embryogenesis.
The animals were sacrificed by decapitation on days [18] [19] times the recommended human dose. 11 It is also possible that no teratogenic effect was seen in this study because once-daily dosing acutely exposed the fetuses to relatively small amounts of zidovudine.
However, in a study from our laboratory using pregnant Long-Evans rats, the agent was concentrated in fetal and placental tissues when administered as a single oral dose of 30 mg/kg/day. Fetal and placental zidovudine levels remained elevated 6 h after maternal administration despite a rapid clearance from the maternal circulation. 1) Caution must be used in the extrapolation of findings from animal teratology studies and their application to the human situation. Of more than 2,000 drugs that have been tested in animal models, approximately 55% were associated with congenital anomalies at high doses. Conversely, there are only 30-40 known human teratogens. 23'24 Importantly, the sensitivity of animal models for teratology studies is not 100%. Thalidomide, one of the most highly publicized and tragic human teratogens, shows species-specific teratogenesis and is 25 only a very weak teratogen in rats.
The teratogenicity of zidovudine in humans is an important issue. Twenty to fifty percent of the infants of HIV-infected women will contract the uniformly fatal disease AIDS. 4 Zidovudine has the ability to decrease the viral antigenemia in vivo and to inhibit replication and infectivity of the virus in vitro; it also has a profound effect on the frequency and severity of neonatal infection. 4'26'27 Zidovudine has no proven teratogenic activity in rats.
However, reliable statements about human teratogenicity of zidovudine must await studies of the offspring of nonhuman primates or humans who were exposed to the drug during early prenatal development. These results strongly suggest that zidovudine may be detrimental to early embryonic development, possibly related to inhibited cell hyperplasia. Embryofetal lethality is an indicated risk of zidovudine therapy during early pregnancy.
